Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-12

Clinical Trial Update: Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating EYP001a with nucleos(t)ide analogs in chronic hepatitis B; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EYP001a (EYP001a)

Snippet

Sponsor: Enyo Pharma | Conditions: Hepatitis B, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2022-10-12